EFNS guidelines on the diagnostic approach to pauci- or asymptomatic hyperCKemia

European Journal of Neurology

Volumn 17, Issue 6, 2010, Pages 767-773

  Kyriakides, T ^a   Angelini, C ^b   Schaefer, J ^c   Sacconi, S ^d   Siciliano, G ^e   Vilchez, J J ^f   Hilton Jones, D ^g  

^a CYPRUS INSTITUTE OF NEUROLOGY AND GENETICS   (Cyprus)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d UNIVERSITY HOSPITAL OF NICE   (France)

^e UNIVERSITY OF PISA   (Italy)

^f HOSPITAL UNIVERSITARIO LA FE   (Spain)

^g JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Asymptomatic; HyperC Kemia; Investigation; Pauci symptomatic

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COLCHICINE; CREATINE KINASE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOTRETINOIN; NEUROLEPTIC AGENT; ZIDOVUDINE;

DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC PROCEDURE; ELECTROMYOGRAPHY; ENZYME ACTIVITY; EVIDENCE BASED MEDICINE; FAMILY HISTORY; HUMAN; HYPERCKEMIA; INBORN ERROR OF METABOLISM; MALIGNANT HYPERTHERMIA; MUSCLE BIOPSY; MUSCULAR DYSTROPHY; MYOPATHY; NEUROMUSCULAR DISEASE; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; BLOOD; ENZYMOLOGY; FEMALE; MUSCULAR DISEASES; REFERENCE VALUE;

CREATINE KINASE; FEMALE; HUMANS; MUSCULAR DISEASES; REFERENCE VALUES;

EID: 77952491243     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2010.03012.x     Document Type: Review

References (34)

1. Sewright KA, Hubal MJ, Kearns A, Holbrook MT, Clarkson PM. Sex differences in response to maximal eccentric exercise. Med Sci Sports Exerc 2008 40 : 242 251.
2. Glueck CJ, Rawal B, Khan NA, Yeramaneni S, Goldenberg N, Wang P. Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia? Metabolism 2009 58 : 233 238.
3. Nardin RA, Zarrin AR, Horowitz GL, Tarulli AW. Effect of newly proposed CK reference limits on neuromuscular diagnosis. Muscle Nerve 2009 39 : 494 497.
4. Brewster LM, Mairuhu G, Sturk A, van Montfrans GA. Distribution of creatine kinase in the general population: implications for statin therapy. Am Heart J 2007 154 : 655 661.
5. Morandi L, Angelini C, Prelle A, et al. High plasma creatine kinase: review of the literature and proposal for a diagnostic algorithm. Neurol Sci 2006 27 : 303 311.
6. Brainin M, Barnes M, Baron JC, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2004. Eur J Neurol 2004 11 : 577 581.
7. Rowland LPWJ, Cerri C, DiMauro S, Miranda A. Approaches to the membrane theory of Duchenne muscular dystrophy. In : Angelini C, Danielli GA, Fontanari D, eds. Muscular Dystrophy Research: Advances and New Trends, Amsterdam. Excerpta Med 1980 3 13.
8. Capasso M, De Angelis MV, Di Muzio A, et al. Familial idiopathic hyper-CK-emia: an underrecognized condition. Muscle Nerve 2006 33 : 760 765.
9. Prelle A, Tancredi L, Sciacco M, et al. Retrospective study of a large population of patients with asymptomatic or minimally symptomatic raised serum creatine kinase levels. J Neurol 2002 249 : 305 311.
10. Simmons Z, Peterlin BL, Boyer PJ, Towfighi J. Muscle biopsy in the evaluation of patients with modestly elevated creatine kinase levels. Muscle Nerve 2003 27 : 242 244.
11. Reijneveld JC, Notermans NC, Linssen WH, Bar PR, Wokke JH. Hyper-CK-aemia revisited. Neuromuscul Disord 2001 11 : 163 164.
12. Fernandez C, de Paula AM, Figarella-Branger D, et al. Diagnostic evaluation of clinically normal subjects with chronic hyperCKemia. Neurology 2006 66 : 1585 1587.
13. Filosto M, Tonin P, Vattemi G, et al. The role of muscle biopsy in investigating isolated muscle pain. Neurology 2007 68 : 181 186.
14. Joy JL, Oh SJ. Asymptomatic hyper-CK-emia: an electrophysiologic and histopathologic study. Muscle Nerve 1989 12 : 206 209.
15. Dabby R, Sadeh M, Herman O, et al. Asymptomatic or minimally symptomatic hyperCKemia: histopathologic correlates. Isr Med Assoc J 2006 8 : 110 113.
16. Malandrini A, Orrico A, Gaudiano C, et al. Muscle biopsy and in vitro contracture test in subjects with idiopathic HyperCKemia. Anesthesiology 2008 109 : 625 628.
17. Carbone I, Bruno C, Sotgia F, et al. Mutation in the CAV3 gene causes partial caveolin-3 deficiency and hyperCKemia. Neurology 2000 54 : 1373 1376.
18. Woodman SE, Sotgia F, Galbiati F, Minetti C, Lisanti MP. Caveolinopathies: mutations in caveolin-3 cause four distinct autosomal dominant muscle diseases. Neurology 2004 62 : 538 543.
19. Merlini L, Carbone I, Capanni C, et al. Familial isolated hyperCKaemia associated with a new mutation in the caveolin-3 (CAV-3) gene. J Neurol Neurosurg Psychiatry 2002 73 : 65 67.
20. Hanisch F, Muller CR, Grimm D, et al. Frequency of calpain-3 c.550delA mutation in limb girdle muscular dystrophy type 2 and isolated hyperCKemia in German patients. Clin Neuropathol 2007 26 : 157 163.
21. Fanin M, Nascimbeni AC, Aurino S, et al. Frequency of LGMD gene mutations in Italian patients with distinct clinical phenotypes. Neurology 2009 72 : 1432 1435.
22. Prelle A, Rigoletto C, Moggio M, et al. Asymptomatic familial hyperCKemia associated with desmin accumulation in skeletal muscle. J Neurol Sci 1996 140 : 132 136.
23. Strach K, Sommer T, Grohe C, et al. Clinical, genetic, and cardiac magnetic resonance imaging findings in primary desminopathies. Neuromuscul Disord 2008 18 : 475 482.
24. Nguyen K, Bassez G, Krahn M, et al. Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes. Arch Neurol 2007 64 : 1176 1182.
25. Boito CA, Melacini P, Vianello A, et al. Clinical and molecular characterization of patients with limb-girdle muscular dystrophy type 2I. Arch Neurol 2005 62 : 1894 1899.
26. Ferreiro V, Giliberto F, Muniz GM, et al. Asymptomatic Becker muscular dystrophy in a family with a multiexon deletion. Muscle Nerve 2009 39 : 239 243.
27. Ramelli GP, Joncourt F, Luetschg J, Weis J, Tolnay M, Burgunder JM. Becker muscular dystrophy with marked divergence between clinical and molecular genetic findings: case series. Swiss Med Wkly 2006 136 : 189 193.
28. Hoffman EP, Arahata K, Minetti C, Bonilla E, Rowland LP. Dystrophinopathy in isolated cases of myopathy in females. Neurology 1992 42 : 967 975.
29. Doriguzzi C, Palmucci L, Mongini T, Chiado-Piat L, Maniscalco M, Restagno G. Systematic use of dystrophin testing in muscle biopsies: results in 201 cases. Eur J Clin Invest 1997 27 : 352 358.
30. Angelini C, Fanin M, Menegazzo E, Freda MP, Duggan DJ, Hoffman EP. Homozygous alpha-sarcoglycan mutation in two siblings: one asymptomatic and one steroid-responsive mild limb-girdle muscular dystrophy patient. Muscle Nerve 1998 21 : 769 775.
31. Merlini L, Sabatelli P, Columbaro M, et al. Hyper-CK-emia as the sole manifestation of myotonic dystrophy type 2. Muscle Nerve 2005 31 : 764 767.
32. D'Adda E, Sciacco M, Fruguglietti ME, et al. Follow-up of a large population of asymptomatic/oligosymptomatic hyperckemic subjects. J Neurol 2006 253 : 1399 1403.
33. Reijneveld JC, Notermans NC, Linssen WH, Wokke JH. Benign prognosis in idiopathic hyper-CK-emia. Muscle Nerve 2000 23 : 575 579.
34. Weglinski MR, Wedel DJ, Engel AG. Malignant hyperthermia testing in patients with persistently increased serum creatine kinase levels. Anesth Analg 1997 84 : 1038 1041.